Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accounts Payables (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Accounts Payables for 3 consecutive years, with $355000.0 as the latest value for Q4 2025.

  • For Q4 2025, Accounts Payables fell 68.33% year-over-year to $355000.0; the TTM value through Dec 2025 reached $355000.0, down 68.33%, while the annual FY2025 figure was $355000.0, 68.33% down from the prior year.
  • Accounts Payables hit $355000.0 in Q4 2025 for Artiva Biotherapeutics, down from $848000.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $2.0 million in Q1 2025 and bottomed at $355000.0 in Q4 2025.
  • Average Accounts Payables over 3 years is $1.0 million, with a median of $984500.0 recorded in 2024.
  • Year-over-year, Accounts Payables soared 82.57% in 2024 and then tumbled 68.33% in 2025.
  • Artiva Biotherapeutics' Accounts Payables stood at $614000.0 in 2023, then soared by 82.57% to $1.1 million in 2024, then crashed by 68.33% to $355000.0 in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $355000.0, $848000.0, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.